OncoTracker Expands Multiple Myeloma Intellectual Property

WEST HOLLYWOOD, Calif., March 12, 2019 /PRNewswire/ — OncoTracker, Inc. announced that it has strengthened its intellectual property portfolio in multiple myeloma by completing an agreement with the Institute for Myeloma and Bone Cancer Research to acquire worldwide rights to its intellectual property regarding both diagnostic testing and a new therapeutic approach for treating these patients.…

OncoTracker CEO to Speak at 20th Annual SoCalBio Conference

WEST HOLLYWOOD, Calif., Sept. 24, 2018 /PRNewswire/ — OncoTracker, Inc. announced that its Chief Executive Officer, James Kuo, MD, MBA, has been invited to speak at the 20th Annual SoCalBio Conference taking place on Friday, September 28, 2018. Dr. Kuo will provide an update on OncoTracker’s recent business activities and answer questions about the company. The conference will be held at the Westin Hotel in Long Beach, California. More information can be found at www.socalbio.org. …

OncoTracker Appoints James Kuo as CEO

WEST HOLLYWOOD, Calif., Aug. 20, 2018 /PRNewswire/ — OncoTracker, Inc. announced the appointment of James Kuo, MD, MBA, as its Chief Executive Officer.  Dr. Kuo is a biotech executive with more than 20 years of experience in corporate development, finance and licensing.

Previously, Dr. Kuo served as Managing Director at Athena Bioventures.  In addition, he has been Chairman and CEO at Synthetic Biologics and BioMicro Systems.  Earlier in his career, he was Managing Director at HealthCare Ventures…

OncoTracker Signs Licensing Agreement with Juno Therapeutics; Provides Update on Internal Development

Los Angeles, CA – December 4, 2017 — OncoTracker, Inc., a private medical diagnostics company, announced a license agreement with Juno Therapeutics (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, to advance its program in multiple myeloma using gamma secretase inhibitors (GSIs) in combination with BCMA-directed CAR T cells. …